• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Pharmacotherapy: Cardiovascular effects of aldosterone blockade in CKD.

作者信息

Pitt Bertram

机构信息

Division of Cardiology, Department of Internal Medicine, University of Michigan School of Medicine, Ann Arbor, MI 48109, USA.

出版信息

Nat Rev Cardiol. 2009 Nov;6(11):679-80. doi: 10.1038/nrcardio.2009.175.

DOI:10.1038/nrcardio.2009.175
PMID:19851348
Abstract
摘要

相似文献

1
Pharmacotherapy: Cardiovascular effects of aldosterone blockade in CKD.药物治疗：慢性肾脏病中醛固酮阻断的心血管效应
Nat Rev Cardiol. 2009 Nov;6(11):679-80. doi: 10.1038/nrcardio.2009.175.
2
Spironolactone is secure and reduces left ventricular hypertrophy in hemodialysis patients.螺内酯对血液透析患者安全且可减轻左心室肥厚。
Ther Adv Cardiovasc Dis. 2015 Aug;9(4):158-67. doi: 10.1177/1753944715591448. Epub 2015 Jun 26.
3
Review article: eplerenone: an underused medication?综述文章：依普利酮：一种未被充分应用的药物？
J Cardiovasc Pharmacol Ther. 2010 Dec;15(4):318-25. doi: 10.1177/1074248410371946. Epub 2010 Sep 27.
4
Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study.慢性肾脏病患者中醛固酮拮抗剂与蛋白尿：一项非对照试验研究
Am J Kidney Dis. 2005 Jul;46(1):45-51. doi: 10.1053/j.ajkd.2005.03.007.
5
Spironolactone in chronic hemodialysis patients improves cardiac function.慢性血液透析患者使用螺内酯可改善心脏功能。
Saudi J Kidney Dis Transpl. 2009 May;20(3):392-7.
6
Spironolactone therapy in heart failure patients with chronic kidney disease.慢性肾脏病心力衰竭患者的螺内酯治疗
Clin Cardiol. 2009 Oct;32(10):597. doi: 10.1002/clc.20670.
7
The risks and benefits of aldosterone antagonists.醛固酮拮抗剂的风险与益处。
Curr Heart Fail Rep. 2005 Aug;2(2):65-71. doi: 10.1007/s11897-005-0011-5.
8
Effect of spironolactone on diastolic function in hypertensive left ventricular hypertrophy.螺内酯对高血压性左心室肥厚舒张功能的影响。
J Hum Hypertens. 2015 Apr;29(4):241-6. doi: 10.1038/jhh.2014.83. Epub 2014 Sep 18.
9
Treatment considerations with aldosterone receptor antagonists.醛固酮受体拮抗剂的治疗考量
J Clin Hypertens (Greenwich). 2011 Jan;13(1):65-9. doi: 10.1111/j.1751-7176.2010.00377.x. Epub 2010 Oct 4.
10
Life-threatening hyperkalemia: a complication of spironolactone for heart failure in a patient with renal insufficiency.危及生命的高钾血症：一名肾功能不全患者因使用螺内酯治疗心力衰竭而引发的并发症。
Anesth Analg. 2002 Jul;95(1):39-41, table of contents. doi: 10.1097/00000539-200207000-00006.

引用本文的文献

1
Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial-a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial.慢性肾脏病中醛固酮受体拮抗作用的益处（BARACK D）试验——一项多中心、前瞻性、随机、开放、盲终点的研究，对2616例初级保健中患有3b期慢性肾脏病的患者进行为期36个月的研究，以比较在常规治疗基础上加用每日一次25毫克螺内酯对死亡率和心血管结局的疗效与单纯常规治疗的疗效：一项随机对照试验的研究方案
Trials. 2014 May 8;15:160. doi: 10.1186/1745-6215-15-160.
2
The safety and tolerability of spironolactone in patients with mild to moderate chronic kidney disease.螺内酯治疗轻中度慢性肾脏病患者的安全性和耐受性。
Br J Clin Pharmacol. 2012 Mar;73(3):447-54. doi: 10.1111/j.1365-2125.2011.04102.x.

本文引用的文献

1
Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial.螺内酯对早期慢性肾脏病左心室质量和主动脉僵硬度的影响：一项随机对照试验
J Am Coll Cardiol. 2009 Aug 4;54(6):505-12. doi: 10.1016/j.jacc.2009.03.066.
2
Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension.叙述性综述：醛固酮在代谢综合征和顽固性高血压中的作用所产生的新临床意义
Ann Intern Med. 2009 Jun 2;150(11):776-83. doi: 10.7326/0003-4819-150-11-200906020-00005.
3
Mechanisms of impaired potassium handling with dual renin-angiotensin-aldosterone blockade in chronic kidney disease.
慢性肾脏病中双重肾素-血管紧张素-醛固酮阻断导致钾处理受损的机制
Hypertension. 2009 May;53(5):754-60. doi: 10.1161/HYPERTENSIONAHA.108.125252. Epub 2009 Mar 23.
4
Drug Insight: eplerenone, a mineralocorticoid-receptor antagonist.药物洞察：依普利酮，一种盐皮质激素受体拮抗剂。
Nat Clin Pract Endocrinol Metab. 2008 Jan;4(1):44-52. doi: 10.1038/ncpendmet0676.
5
Aldosterone blockade: an emerging strategy for abrogating progressive renal disease.醛固酮阻断：一种消除进行性肾病的新兴策略。
Am J Med. 2006 Nov;119(11):912-9. doi: 10.1016/j.amjmed.2006.03.038.
6
Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study.随机螺内酯评估研究发表后的高钾血症发生率。
N Engl J Med. 2004 Aug 5;351(6):543-51. doi: 10.1056/NEJMoa040135.
7
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.依普利酮，一种选择性醛固酮阻滞剂，用于心肌梗死后左心室功能不全的患者。
N Engl J Med. 2003 Apr 3;348(14):1309-21. doi: 10.1056/NEJMoa030207. Epub 2003 Mar 31.
8
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.螺内酯对重度心力衰竭患者发病率和死亡率的影响。随机螺内酯评估研究调查组。
N Engl J Med. 1999 Sep 2;341(10):709-17. doi: 10.1056/NEJM199909023411001.